Marty Makary, a target of industry and anti-abortion activists, out at FDA
The article presents Makary's departure through multiple institutional pressures (White House, pharmaceutical industry, anti-abortion activists, GOP advisers) without editorial judgment on the merits of any position. Language is largely factual and attributed ('reportedly,' 'according to,' 'advocates argue'). However, framing tilts slightly toward establishment legitimacy by centering Trump administration priorities and industry/GOP faction concerns equally, while anti-abortion and pharmaceutical industry positions receive more substantive explanation than potential counterarguments.
Primary voices: elected official, state or recognized government, media outlet, academic or expert, anonymous source
- This article does not address specific public health or scientific rationales behind Makary's or Prasad's regulatory decisions (e.g., evidence on fruit-flavored vape risks, mifepristone safety data, or Moderna vaccine trial results).
- This article does not include statements from Makary, Prasad, or the FDA defending their positions or explaining their regulatory reasoning.
- This article does not contextualize industry criticism of regulatory unpredictability with specific examples or independent analysis of FDA approval timelines under Makary versus predecessors.
Framing may shift if Makary or FDA staff provide public comment post-resignation, or if successor Diamantas's confirmation process reveals additional context about internal conflicts.
Government-sourcedEstablishment framingNeutral language
Food and Drug Administration Commissioner Marty Makary is set to leave his post on Tuesday, making him the latest in the line of Trump health officials to be ousted this term.
Makary, previously a Johns Hopkins University professor of surgery, has been at the center of a number of conflicts in recent weeks, including over vaping, abortion, and drug policy. He is set to resign on Tuesday, according to multiple reports citing agency sources. It had been reported that President Donald Trump was moving to fire him.
The news broke before Makary was scheduled to testify in front of the Senate Appropriations Committee on Wednesday morning to defend the president’s 2027 budget proposal for his agency.
The various headaches for the administration coming from the FDA have been a sore spot for the Department of Health and Human Services and the White House, as GOP advisers have been reshaping the party’s healthcare agenda ahead of the midterm elections.
Earlier this month, Trump reportedly criticized Makary for failing to approve fruit-flavored vape products, which critics say will entice children and adolescents to take up nicotine.
Shortly thereafter, the FDA announced the approval of four new vape flavors, including, for the first time, two fruit-flavored products: blueberry and mango.
Anti-abortion advocates within the GOP have also increased pressure on the administration to fire Makary over the agency’s decision not to reinstitute in-person dispensing requirements for the abortion pill mifepristone.
The FDA removed the in-person dispensing requirement for mifepristone in 2023, during the Biden administration, allowing the abortion medication to be bought and sold online.
Conservative Republicans and the anti-abortion lobby also slammed the Trump administration in October 2025 when Makary and FDA staff approved a new generic version of mifepristone.
Anti-abortion advocates contend that not reversing the Biden-era rule change to restore in-person screening mandates will hurt the GOP in the midterm elections by depressing voter turnout.
Pharmaceutical companies have also put pressure on the Trump administration to axe Makary after a series of high-profile conflicts over the agency’s approval processes, which industry advocates argue have created a culture of unpredictability at the regulatory agency.
Makary’s backing of Dr. Vinay Prasad, whom he hand-selected to be the agency’s head of vaccines and gene therapies, has been a sore spot between the agency and the industry.
Prasad, who left the agency on Thursday, shocked the pharmaceutical industry by not approving Moderna’s new flu vaccine after the company followed instructions laid out by the Biden administration for safety and efficacy testing. Prasad also clashed with developers of novel treatments for rare diseases, despite promising to fast-track cures.
Makary is the third Senate-confirmed HHS official to leave the department.
Last summer, Trump fired the Centers for Disease Control and Prevention director, Susan Monarez, following a public disagreement with HHS Secretary Robert F. Kennedy Jr. over his requests to change the childhood vaccine schedule.
Former HHS Deputy Secretary Jim O’Neill, who replaced Monarez in an acting capacity from August 2025 until March, was abruptly removed from the department this spring and installed as the director of the National Science Foundation instead.
The HHS leadership team has also been missing a surgeon general for the entirety of Trump’s second term. The president’s first two nominees for the post, Dr. Janette Nesheiwat and Dr. Casey Means, did not have the support within the Senate to progress through the confirmation process.
It is speculated that Trump will replace Makary with Kyle Diamantas, the FDA deputy commissioner for human foods and one of the chief architects of the 2025 Dietary Guidelines for Americans, which has been branded a major policy victory for the Make America Healthy Again coalition.
Comments
No comments yet. Be the first.
Sign in to leave a comment.